CLIP3 and glioblastoma: Overall, this study suggests that radioresistant GBM cells that survive after radiotherapy exhibit increased stemness and glycolytic activity mediated by the Spy1-CLIP3 axis, and that glimepiride by activating CLIP3 can achieve high-efficiency radiosensitization with low toxicity (Fig. 7E).